Cetuximab as treatment for head and neck cancer patients with a previous liver transplant: report of two cases

References

• Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21:2787–99.10.1200/JCO.2003.01.504
   PubMed Web of Science ®Google Scholar
• Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995;1:1311–18.
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2005;354(6):567–78.
   Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.10.1056/NEJMoa0802656
   PubMed Web of Science ®Google Scholar
• Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, Garcia-Saenz JA. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23(4):1016–22.10.1093/annonc/mdr367
   PubMed Web of Science ®Google Scholar
• Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007;110(3):581–89.10.1002/(ISSN)1097-0142
   PubMed Web of Science ®Google Scholar
• European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. The Lancet. 1994;344(8920):423–28.
   PubMed Web of Science ®Google Scholar
• Jiménez-Romero C, Justo-Alonso I, Cambra-Molero F, Calvo-Pulido J, García-Sesma A, l Abradelo-Usera M, et al. Incidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosis. World J Hepatol. 2015;7(7):942–53.10.4254/wjh.v7.i7.942
   PubMedGoogle Scholar
• De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012;12:3008–20.10.1111/j.1600-6143.2012.04212.x
   PubMed Web of Science ®Google Scholar
• Courtney K, Corcoran R, Engelman J. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6):1075–83.10.1200/JCO.2009.25.3641
   PubMed Web of Science ®Google Scholar
• Fury MG, Sherman E, Ho AL, Xiao H, Tsai F, Nwankwo O, et al. A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer. Cancer. 2013;119(10):1823–31.10.1002/cncr.27986
   PubMed Web of Science ®Google Scholar
• Fury MG, Lee NY, Sherman E, Ho AL, Rao S, Heguy A, et al. A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2013;87(3):479–86.10.1016/j.ijrobp.2013.06.2043
   PubMed Web of Science ®Google Scholar
• Saba NF, Hurwitz SJ, Magliocca K, Kim S, Owonikoko TK, Harvey D, et al. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer. 2014;120(24):3940–51.10.1002/cncr.28965
   PubMed Web of Science ®Google Scholar
• Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011;11(9):777–92.10.4161/cbt.11.9.15050
   PubMed Web of Science ®Google Scholar
• Ciunci CA, Perini RF, Avadhani AN, Kang HC, Sun W, Redlinger M, et al. Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Cancer. 2014;120(1):77–85.10.1002/cncr.28294
   PubMed Web of Science ®Google Scholar
• Kordes S, Richel DJ, Klümpen HJ, Weterman MJ, Stevens AJ, Wilmink JW. A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer. Invest New Drugs. 2013;31:85–91.10.1007/s10637-012-9802-1
   PubMed Web of Science ®Google Scholar
• Bozec A, Etienne-Grimaldi MC, Fischel JL, Sudaka A, Toussan N, Formento P, et al. The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab–bevacizumab–irradiation combination on head and neck cancer xenografts. Oral Oncol. 2011;47:340–44.10.1016/j.oraloncology.2011.02.020
   PubMed Web of Science ®Google Scholar
• Stange BJ, Glanemann M, Nuessler NC, Settmacher U, Steinmüller T, Neuhaus P. Hepatic artery thrombosis after adult liver transplantation. Liver Transpl. 2003;9(6):612–20.10.1053/jlts.2003.50098
   PubMed Web of Science ®Google Scholar
• Schreckenbach T, Liese J, Bechstein WO, Moench C. Posthepatectomy liver failure. Digestive Surg. 2012;29(1):79–85.10.1159/000335741
   PubMed Web of Science ®Google Scholar
• Mydin and Armstrong. Radiotherapy plus cetuximab is safe in a head and neck cancer patient on immunosuppressants for liver transplant. Clin Oncol. 2007;19(5):356–66.
   Web of Science ®Google Scholar
• Leard LE, Cho BK, Jones KD, Hays SR, Tope WD, Golden JA, et al. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant. 2007;26(12):1340–44.10.1016/j.healun.2007.09.019
   PubMed Web of Science ®Google Scholar
• Peerzada MM, Spiro TP, Daw HA. Pulmonary toxicities of biologics: a review. Anti-Cancer Drugs. 2010;21(2):131–39.10.1097/CAD.0b013e328333d662
   PubMed Web of Science ®Google Scholar
• Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007;18:510–17.
   PubMed Web of Science ®Google Scholar